Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study

Bibliography

• Gupta V. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab 2013;17:413-21
   PubMedGoogle Scholar
• Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009;31:2472-88
   PubMed Web of Science ®Google Scholar
• Herzlinger S, Horton ES. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. Diabetes Res Clin Pract 2013;100:1-10
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, et al. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs 2009;18:1495-503
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog. liraglutide. Int J Obes (Lond) 2012;36:843-54
   PubMed Web of Science ®Google Scholar
• Amato A, Baldassano S, Liotta R, et al. Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle. J Endocrinol 2014;221:29-37
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53
   PubMedGoogle Scholar
• Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-53
   PubMed Web of Science ®Google Scholar
• Tushuizen ME, Bunck MC, Pouwels PJ, et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-17
   PubMed Web of Science ®Google Scholar
• Kenny PR, Brady DE, Torres DM, et al. Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. Am J Gastroenterol 2010;105:2707-9
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013;37:234-42
   PubMed Web of Science ®Google Scholar
• Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 2012;7:e50117
   PubMed Web of Science ®Google Scholar
• Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications 2013;27:401-6
   PubMed Web of Science ®Google Scholar
• Sathyanarayana P, Jogi M, Muthupillai R, et al. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 2011;19:2310-15
   PubMed Web of Science ®Google Scholar
• Gupta NA, Kolachala VL, Jiang R, et al. The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol 2012;181:1693-701
   PubMed Web of Science ®Google Scholar
• Brea A, Mosquera D, Martin E, et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005;25:1045-50
   PubMed Web of Science ®Google Scholar
• Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5
   PubMed Web of Science ®Google Scholar
• Nagele U, Hagele EO, Sauer G, et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem 1984;22:165-74
   PubMedGoogle Scholar
• Warnick GR, Nguyen T, Albers AA. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem 1985;31:217-22
   PubMed Web of Science ®Google Scholar
• Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006;37:482-6
   PubMed Web of Science ®Google Scholar
• Needleman L, Kurtz AB, Rifkin MD, et al. Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. AJR Am J Roentgenol 1986;146:1011-15
   PubMed Web of Science ®Google Scholar
• Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 2008;31:165-9
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23:403-9
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011;31:1285-97
   PubMed Web of Science ®Google Scholar
• Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1584-92
   PubMed Web of Science ®Google Scholar
• Wang XC, Gusdon AM, Liu H, Qu S. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. World J Gastroenterol 2014;20:14821-30
   PubMed Web of Science ®Google Scholar
• Liu Y, Wei R, Hong TP. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:9090-7
   PubMed Web of Science ®Google Scholar
• Leach NV, Dronca E, Vesa SC, et al. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis. Eur J Intern Med 2014;25:762-7
   PubMed Web of Science ®Google Scholar
• Rizzo M, Abate N, Chandalia M, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab 2015;100:603-6
   PubMed Web of Science ®Google Scholar
• Hogan AE, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 2014;57:781-4
   PubMed Web of Science ®Google Scholar
• Rizzo M, Nikolic D, Banach M, et al. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives. Clin Lipidol 2013;8:173-81
   Web of Science ®Google Scholar
• Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med 2012;29:1115-18
   PubMed Web of Science ®Google Scholar
• Nandy D, Johnson C, Basu R, et al. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res 2014;11:419-30
   PubMed Web of Science ®Google Scholar
• Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal 2012;2012:496453
   PubMed Web of Science ®Google Scholar
• Sonmez A, Nikolic D, Dogru T, et al. Low- and high-density lipoprotein subclasses in subjects with non-alcoholic fatty liver disease. Journal of Clinical Lipidology 2015
   PubMed Web of Science ®Google Scholar
• Toth PP, Barylski M, Nikolic D, et al. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab 2014;28:353-68
   PubMed Web of Science ®Google Scholar
• Tang A, Rabasa-Lhoret R, Castel H, et al. Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: A randomized trial. Diabetes Care 2015;38(7):1339-46
   PubMed Web of Science ®Google Scholar
• Puig J, Blasco G, Daunis IEJ, et al. Nonalcoholic fatty liver disease and age are strong indicators for atherosclerosis in morbid obesity. Clin Endocrinol (Oxf) 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol 2014;13:49
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER®). Available from: https://clinicaltrials.gov/ct2/show/NCT01179048
   Google Scholar
• Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009;204:521-5
   PubMed Web of Science ®Google Scholar